Argus analyst David Toung raised the firm’s price target on Silk Road Medical to $32 from $24 and keeps a Buy rating on the shares. The company recently launched the NPS PLUS and the tapered carotid stent, and with several quarters of solid financial results, Silk Road Medical is continuing on its path to operating profitability, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SILK:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue